FindTrial
Sign In

A comparative study of safety and efficacy of bilastine updosing (40mg) vs combination of bilastine 20mg with levocetrizine 5mg in the treatment of chronic spontaneous urticaria

A prospective randomized study of safety and efficacy of bilastine updosing (40mg) vs combination of bilastine 20mg with levocetrizine 5mg in the treatment of chronic spontaneous urticaria

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046449
Enrollment
60
Registered
2022-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L49-L54- Urticaria and erythema

Interventions

Intervention1: non responders will be started on Tablet Bilastine 20mg bd that is Updosing bilastine to 40mg: All the patients will be started on T.Bilastine 20mg . They will be asked to record sympt

Sponsors

SRM Medical college hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients previously treated with bilastine 20mg for 2 weeks but developing new lesions

Exclusion criteria

Exclusion criteria: Hereditary angioedema Food or drug allergy Collagen vascular diseases Atopic dermatitis Systemic autoimmune disorders Hodgkinââ?¬•s disease Pregnant and lactating women Patients on systemic or topical corticosteroids within 4 weeks

Design outcomes

Primary

MeasureTime frame
To compare effectiveness of Bilastine updosing v/s combination of 20mg Bilastine with 5mg Levocetrizine in treatment of chronic spontaneous urticariaTimepoint: 6weeks—

Secondary

MeasureTime frame
To assess safety, tolerability and side effects of Bilastine updosing v/s Bilastine with Levocetrizine in the treatment of chronic spontaneous urticaria Timepoint: 6weeks—

Countries

India

Contacts

Public ContactBoggarapu Sneha

SRM INSTITUTE OF SCIENCE AND TECHNOLOGY

muralin1@srmist.edu.in9840168711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026